Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
2022-002695-37Phase 2Active
- Sponsor
- Ipsen
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Elafibranor with Placebo (2 arms). Primary endpoint: Primary endpoints during the 12-week double-blind period. Started Dec 2022; status: active.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2022-002695-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002695-37.